Clinical Study on the Treatment of Type 1 Diabetes With CNK-UT009 Cell Injection

Summary

This is a single-arm, open, investigator-initiated clinical study of CNK-UT009 cell injection in patients with type 1 diabetes. The purpose of this study is to evaluate the safety and tolerability of CNK-UT009 cell injection in patients with type 1 diabetes mellitus, determine the maximum tolerated dose (MTD), and evaluate the initial therapeutic effectiveness, PK characteristics and immunogenicity of CNK-UT009 cell injection. And the effect of CNK-UT009 cell injection on peripheral blood immune cells and serum cytokines.

Timeline

Start

2025-05-06

Primary completion

2026-12-31

Completion

2026-12-31

Drugs

Indications